Canada Markets closed

Mind Medicine (MindMed) Inc. (MMED.NE)

NEO - NEO Real Time Price. Currency in CAD
Add to watchlist
1.3000+0.3300 (+34.02%)
At close: 04:26PM EDT
Full screen
Previous Close0.9700
Open1.4500
Bid1.2200 x N/A
Ask1.3400 x N/A
Day's Range1.1600 - 1.7100
52 Week Range0.6200 - 3.8000
Volume6,083,578
Avg. Volume295,656
Market Cap547.563M
Beta (5Y Monthly)1.98
PE Ratio (TTM)N/A
EPS (TTM)-0.2350
Earnings DateMar 28, 2022 - Apr 01, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • CNW Group

    MindMed Strengthens Board with Appointment of Two New Independent Directors

    Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the appointment of Dr. Suzanne Bruhn and Dr. Roger Crystal, effective August 11, 2022 as independent members of its Board of Directors.

  • CNW Group

    MindMed Reports Second Quarter 2022 Financial Results and Business Highlights

    Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today reported its financial results for the quarter ended June 30, 2022.

  • CNW Group

    MindMed Co-Founder Dr. Scott Freeman Proposes Value Enhancement Plan

    Today, FCM MM HOLDINGS, LLC ("FCM") announced that it has sent a letter to the Board of Directors of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed") calling on the Board to adopt a new strategic plan proposed by FCM including: refocusing on its core drugs, cutting cash burn, and terminating MindMed's at-the-money equity offering. FCM is directed and managed Dr. Scott Freeman, co-founder and former Chief Medical Officer of MindMed, who has offered to provide MindMed his ex